PRECISION Data Platform Reveals mCRPC Treatment Outcomes in Urology Practices – Neal Shore
Zachary Klaassen interviews Neal Shore about real-world treatment patterns for mCRPC patients in community urology centers using the PRECISION database. Dr. Shore analyzes data from over 12,000 mCRPC patients across five years, revealing that community urologists show strong preference for sipuleucel-T and radium-223 as first and second-line therapies, followed by ARPIs, with limited taxane use….